{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:24:38Z","timestamp":1790645078600,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.phrs.2012.12.006","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T23:24:45Z","timestamp":1356996285000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Novel treatment options for epilepsy: Focus on perampanel"],"prefix":"10.1016","volume":"70","author":[{"given":"V.","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Crema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Iudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2012.12.006_bib0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurology"},{"issue":"Suppl. 8","key":"10.1016\/j.phrs.2012.12.006_bib0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2012.12.006_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2012.12.006_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Currents"},{"issue":"November","key":"10.1016\/j.phrs.2012.12.006_bib0025","article-title":"Perampanel \u2013 new promise for refractory epilepsy?","volume":"13","author":"L\u00f6scher","year":"2012","journal-title":"Nature Reviews Neurology (advance online publication)"},{"key":"10.1016\/j.phrs.2012.12.006_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2012.12.006_bib0035","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","author":"French","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2012.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2012.12.006_bib0045","unstructured":"Fycompa. EPAR. Public assessment report [online]. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002434\/human_med_001572.jsp&mid=WC0b01ac058001d124 [accessed 14.11.12]."},{"key":"10.1016\/j.phrs.2012.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2012.12.006_bib0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuint.2012.02.035","article-title":"A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus","volume":"61","author":"Ceolin","year":"2012","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.phrs.2012.12.006_bib0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/13543784.2012.705277","article-title":"New AMPA antagonists in epilepsy","volume":"21","author":"Russo","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.phrs.2012.12.006_bib0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/PL00005060","article-title":"Phenytoin's effect on the spread of seizure activity in the amygdala kindling model","volume":"356","author":"Ebert","year":"1997","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"Suppl. 4S","key":"10.1016\/j.phrs.2012.12.006_bib0070","doi-asserted-by":"crossref","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: review of physiology and pathology","volume":"130","author":"Meldrum","year":"2000","journal-title":"Journal of Nutrition"},{"issue":"3","key":"10.1016\/j.phrs.2012.12.006_bib0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/j.phrs.2012.12.006_bib0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.nbd.2003.11.006","article-title":"RNA editing (R\/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients","volume":"15","author":"Vollmar","year":"2004","journal-title":"Neurobiology of Disease"},{"issue":"4","key":"10.1016\/j.phrs.2012.12.006_bib0085","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0306-4522(99)00392-9","article-title":"Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography","volume":"94","author":"Zilles","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2012.12.006_bib0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0079-6123(02)35046-5","article-title":"Implications for neuroprotective treatments","volume":"135","author":"Meldrum","year":"2002","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.phrs.2012.12.006_bib0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0140-6736(93)90754-5","article-title":"Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain","volume":"341","author":"During","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2012.12.006_bib0100","series-title":"Abstract submitted to the American Epilepsy Society 65th Annual Meeting","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three Phase III trials","author":"Laurenza","year":"2011"},{"key":"10.1016\/j.phrs.2012.12.006_bib0105","first-page":"99","article-title":"Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist","volume":"50","author":"Templeton","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2012.12.006_bib0110","unstructured":"Fycompa. Summary of product characteristics [online]. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002434\/human_med_001572.jsp&mid=WC0b01ac058001d124 [accessed 14.11.12]."},{"key":"10.1016\/j.phrs.2012.12.006_bib0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.phrs.2012.12.006_bib0120","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","author":"Krauss","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2012.12.006_bib0125","first-page":"263","article-title":"Perampanel Study 207: long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor","year":"2012","journal-title":"Acta Neurologica Scandinavica."},{"key":"10.1016\/j.phrs.2012.12.006_bib0130","unstructured":"Fycompa. Prescribing information [online]. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [accessed 17.12.12]."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812002423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812002423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:44:49Z","timestamp":1772880289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661812002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1043661812002423"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2012.12.006","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel treatment options for epilepsy: Focus on perampanel","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}